Timothy J Daskivich1, Lorna Kwan2, Atreya Dash3, Christopher Saigal4, Mark S Litwin5. 1. Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California. Electronic address: tdaskivich@ucla.edu. 2. Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California. 3. Department of Urology, University of Washington, Seattle, Washington. 4. Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California. 5. Jonsson Comprehensive Cancer Center and Department of Health Policy and Management, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California.
Abstract
PURPOSE: Accurate estimation of life expectancy is critical for men considering aggressive vs nonaggressive treatment of early stage prostate cancer. We created an age adjusted comorbidity index that predicts other cause mortality in men with prostate cancer. MATERIALS AND METHODS: We sampled 1,598 men consecutively diagnosed with prostate cancer between 1998 and 2004 at West Los Angeles and Long Beach Veterans Affairs hospitals. We used competing risks regression in testing and validation cohorts to determine the risk of nonprostate cancer related (ie other cause) mortality associated with age at diagnosis and PCCI score. We converted risk into a 10-point scoring system and calculated 2, 5 and 10-year cumulative incidence of other cause mortality by age adjusted PCCI scores. RESULTS: PCCI score and age were associated with similar hazards of other cause mortality in the testing and validation cohorts. Each 6-year increase in age at diagnosis of greater than 60 was equivalent to 1 additional PCCI point. After correcting PCCI score for age the age adjusted PCCI scores were strongly predictive of other cause mortality. The subhazard ratio of other cause mortality vs 0 for a score of 0, 1-2, 3-4, 5-6, 7-9 and 10+ was 2.0 (95% CI 1.3-3.0), 4.0 (95% CI 2.6-6.1), 8.7 (95% CI 5.7-13.3), 14.7 (95% CI 9.4-22.8) and 43.2 (95% CI 26.6-70.4), respectively. The 10-year cumulative incidence of other cause mortality was 10%, 19%, 35%, 60%, 79% and 99%, respectively. CONCLUSIONS: The age adjusted PCCI strongly stratifies the risk of long-term, other cause mortality. It may be incorporated into shared decision making to decrease overtreatment of older and chronically ill men with prostate cancer.
PURPOSE: Accurate estimation of life expectancy is critical for men considering aggressive vs nonaggressive treatment of early stage prostate cancer. We created an age adjusted comorbidity index that predicts other cause mortality in men with prostate cancer. MATERIALS AND METHODS: We sampled 1,598 men consecutively diagnosed with prostate cancer between 1998 and 2004 at West Los Angeles and Long Beach Veterans Affairs hospitals. We used competing risks regression in testing and validation cohorts to determine the risk of nonprostate cancer related (ie other cause) mortality associated with age at diagnosis and PCCI score. We converted risk into a 10-point scoring system and calculated 2, 5 and 10-year cumulative incidence of other cause mortality by age adjusted PCCI scores. RESULTS: PCCI score and age were associated with similar hazards of other cause mortality in the testing and validation cohorts. Each 6-year increase in age at diagnosis of greater than 60 was equivalent to 1 additional PCCI point. After correcting PCCI score for age the age adjusted PCCI scores were strongly predictive of other cause mortality. The subhazard ratio of other cause mortality vs 0 for a score of 0, 1-2, 3-4, 5-6, 7-9 and 10+ was 2.0 (95% CI 1.3-3.0), 4.0 (95% CI 2.6-6.1), 8.7 (95% CI 5.7-13.3), 14.7 (95% CI 9.4-22.8) and 43.2 (95% CI 26.6-70.4), respectively. The 10-year cumulative incidence of other cause mortality was 10%, 19%, 35%, 60%, 79% and 99%, respectively. CONCLUSIONS: The age adjusted PCCI strongly stratifies the risk of long-term, other cause mortality. It may be incorporated into shared decision making to decrease overtreatment of older and chronically ill men with prostate cancer.
Authors: Joo Yong Lee; Ho Won Kang; Koon Ho Rha; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho Journal: J Cancer Res Clin Oncol Date: 2015-12-12 Impact factor: 4.553
Authors: Stephen B Williams; Jinhai Huo; Karim Chamie; Marc C Smaldone; Christopher D Kosarek; Justin E Fang; Leslie A Ynalvez; Simon P Kim; Karen E Hoffman; Sharon H Giordano; Brian F Chapin Journal: Cancer Date: 2017-01-18 Impact factor: 6.860
Authors: Gregory T Chesnut; Amy L Tin; Katherine A Fleshner; Nicole E Benfante; Andrew J Vickers; James A Eastham; Daniel D Sjoberg; Sigrid V Carlsson Journal: Prostate Cancer Prostatic Dis Date: 2021-11-03 Impact factor: 5.554
Authors: Ericka M Sohlberg; I-Chun Thomas; Jaden Yang; Kristopher Kapphahn; Timothy J Daskivich; Ted A Skolarus; Jeremy B Shelton; Danil V Makarov; Jonathan Bergman; Christine Ko Bang; Mary K Goldstein; Todd H Wagner; James D Brooks; Manisha Desai; John T Leppert Journal: Urol Oncol Date: 2020-07-13 Impact factor: 3.498
Authors: Scott C Flanders; Janet Kim; Samuel Wilson; Jeffrey Braziunas; Sheldon Greenfield; John Billimek; Stanislav Lechpammer; Daniel W Lin; Lawrence Karsh; David I Quinn; Daniel Shevrin; Neal D Shore; James T Symanowski; David F Penson Journal: Future Oncol Date: 2018-02-08 Impact factor: 3.404
Authors: Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann Journal: Eur Urol Oncol Date: 2018-06-06
Authors: Michael Froehner; Rainer Koch; Stefan Propping; Dorothea Liebeheim; Matthias Hübler; Gustavo B Baretton; Oliver W Hakenberg; Manfred P Wirth Journal: Asian J Androl Date: 2017 Mar-Apr Impact factor: 3.285
Authors: Simon John Christoph Soerensen; I-Chun Thomas; Bogdana Schmidt; Timothy J Daskivich; Ted A Skolarus; Christian Jackson; Thomas F Osborne; Glenn M Chertow; James D Brooks; David H Rehkopf; John T Leppert Journal: Urology Date: 2021-06-15 Impact factor: 2.633